Bulk Manufacturer of Controlled Substances Application: Siegfried USA, LLC, 32905-32906 [2018-15138]
Download as PDF
<![CDATA[
32905
Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices
Transboundary Hydrocarbon Reservoirs
in the Gulf of Mexico. These eight
stipulations will be added as lease terms
where applicable and will be
enforceable as part of the lease.
Appendix B of the Gulf of Mexico OCS
Oil and Gas Lease Sales: 2017–2022;
Gulf of Mexico Lease Sales 249, 250,
251, 252, 253, 254, 256, 257, 259, and
261; Final Multisale Environmental
Impact Statement provides a list and
description of standard post-lease
conditions of approval that may be
required by BOEM or the Bureau of
Safety and Environmental Enforcement
as a result of plan and permit review
processes for the Gulf of Mexico OCS
Region.
After careful consideration, BOEM
has selected the preferred alternative
(Alternative A) in the 2018 GOM
Supplemental EIS for proposed Lease
Sale 251. BOEM’s selection of the
preferred alternative meets the purpose
and need for the proposed action, as
identified in the 2018 GOM
Supplemental EIS, and provides for
orderly resource development with
protection of the human, marine, and
coastal environments while also
ensuring that the public receives an
equitable return for these resources and
that free-market competition is
maintained.
Authority: This Notice of Availability of a
Record of Decision is published pursuant to
the regulations (40 CFR part 1505)
implementing the provisions of the National
Environmental Policy Act of 1969, as
amended (42 U.S.C. 4321 et seq.).
Dated: July 11, 2018.
Walter D. Cruickshank,
Acting Director, Bureau of Ocean Energy
Management.
[FR Doc. 2018–15181 Filed 7–13–18; 8:45 am]
BILLING CODE 4310–MR–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 731–TA–1374–1376
(Final)]
Citric Acid and Certain Citrate Salts
From Belgium, Colombia, and Thailand
sradovich on DSK3GMQ082PROD with NOTICES
Determination
On the basis of the record 1 developed
in the subject investigations, the United
States International Trade Commission
(‘‘Commission’’) determines, pursuant
to the Tariff Act of 1930 (‘‘the Act’’),
that an industry in the United States is
materially injured by reason of imports
1 The
record is defined in sec. 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR 207.2(f)).
VerDate Sep<11>2014
17:31 Jul 13, 2018
Jkt 244001
of citric acid and certain citrate salts
from Belgium, Colombia, and Thailand
that have been found by the U.S.
Department of Commerce (‘‘Commerce’’)
to be sold in the United States at less
than fair value (‘‘LTFV’’).2 3 4
Background
2 Citric Acid and Certain Citrate Salts from
Thailand: Affirmative Final Determination of Sales
at Less Than Fair Value and Final Affirmative
Determination of Critical Circumstances in Part, 82
FR 25998, June 5, 2018; Citric Acid and Certain
Citrate Salts from Belgium: Affirmative Final
Determination of Sales at Less Than Fair Value, 82
FR 26001, June 5, 2018; Citric Acid and Certain
Citrate Salts from Colombia: Affirmative Final
Determination of Sales at Less Than Fair Value and
Final Negative Determination of Critical
Circumstances, 82 FR 26002, June 5, 2018.
3 The Commission also finds that imports subject
to Commerce’s affirmative critical circumstances
determination are not likely to undermine seriously
the remedial effect of the antidumping duty order
on Thailand.
4 Commissioner Jason E. Kearns did not
participate in these investigations.
Frm 00074
By order of the Commission.
Issued: July 10, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–15067 Filed 7–13–18; 8:45 am]
The Commission, pursuant to section
735(b) of the Act (19 U.S.C. 1673d(b)),
instituted these investigations effective
June 2, 2017, following receipt of a
petition filed with the Commission and
Commerce by Archer Daniels Midland
Company, Decatur, Illinois; Cargill,
Incorporated, Minneapolis, Minnesota;
and Tate & Lyle Ingredients Americas,
LLC, Hoffman Estates, Illinois. The
Commission scheduled the final phase
of the investigations following
notification of a preliminary
determination by Commerce that
imports of citric acid and certain citrate
salts from Belgium, Colombia, and
Thailand were being sold at LTFV
within the meaning of section 733(b) of
the Act (19 U.S.C. 1673b(b)). Notice of
the scheduling of the final phase of the
Commission’s investigation and of a
public hearing to be held in connection
therewith was given by posting copies
of the notice in the Office of the
Secretary, U.S. International Trade
Commission, Washington, DC, and by
publishing the notice in the Federal
Register of February 2, 2018 (83 FR
4922). The hearing was held in
Washington, DC, on May 14, 2018, and
all persons who requested the
opportunity were permitted to appear in
person or by counsel.
The Commission made these
determinations pursuant to section
735(b) of the Act (19 U.S.C. 1673d(b)).
It completed and filed its
determinations in these investigations
on July 10, 2018. The views of the
Commission are contained in USITC
Publication 4799 (July 2018), entitled
Citric Acid and Certain Citrate Salts
from Belgium, Colombia, and Thailand:
PO 00000
Investigation Nos. 731–TA–1374–1376
(Final).
Fmt 4703
Sfmt 4703
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Siegfried
USA, LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 14, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
November 2, 2017, Siegfried USA, LLC,
33 Industrial Park Rd., Pennsville, NJ
08070 applied to be registered as a bulk
manufacturer for the basic classes of
controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled
substance
Gamma Hydroxybutyric Acid.
Dihydromorphine ....
Hydromorphinol ......
E:\FR\FM\16JYN1.SGM
16JYN1
Drug code
Schedule
2010
I
9145
9301
I
I
32906
Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices
Controlled
substance
Drug code
Schedule
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Methylphenidate .....
Amobarbital ............
Pentobarbital ..........
Secobarbital ............
Codeine ..................
Oxycodone .............
Hydromorphone ......
Hydrocodone ..........
Methadone ..............
Methadone intermediate.
Morphine .................
Oripavine ................
Thebaine .................
Opium tincture ........
Oxymorphone .........
1724
2125
2270
2315
9050
9143
9150
9193
9250
9254
II
II
II
II
II
II
II
II
II
II
9300
9330
9333
9630
9652
II
II
II
II
II
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cerilliant Corporation
ACTION:
[FR Doc. 2018–15138 Filed 7–13–18; 8:45 am]
BILLING CODE 4410–09–P
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 15, 2018. Such persons
may also file a written request for a
hearing on the application on or before
August 15, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
DATES:
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
Dated: July 10, 2018.
John J. Martin,
Assistant Administrator.
Notice of application.
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
delegated to the Assistant Administrator
of the DEA Diversion Control Division
(‘‘Assistant Administrator’’) pursuant to
section 7 of 28 CFR part 0, appendix to
subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June
12, 2018, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock,
Texas 78665 applied to be registered as
an importer of the following basic
classes of controlled substances:
sradovich on DSK3GMQ082PROD with NOTICES
Controlled substance
Drug code
3-Fluoro-N-methylcathinone (3–FMC) .............................................................................................................................
Cathinone ........................................................................................................................................................................
Methcathinone .................................................................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) .............................................................................................................................
Pentedrone (a-methylaminovalerophenone) ...................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ....................................................................................................................
4-Methyl-N-ethylcathinone (4–MEC) ...............................................................................................................................
Naphyrone .......................................................................................................................................................................
N-Ethylamphetamine .......................................................................................................................................................
N,N-Dimethylamphetamine ..............................................................................................................................................
Fenethylline .....................................................................................................................................................................
Methaqualone ..................................................................................................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ..................................................................................................
SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoropentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ..................
AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....................
JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ......................................................................................................................
AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .........................................
THJ–2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone ...................................................................
AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide .................
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .................................
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide ..............................................................
JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ..................................................................................................
SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole ....................................................................
JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ..............................................................................
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) .....................................................................................................
UR–144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................
JWH–073 (1-Butyl-3-(1-naphthoyl)indole) .......................................................................................................................
JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ..........................................................................................
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) .......................................................................................................
JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ......................................................................................................
PB–22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .................................................................................................
5F–PB–22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) ............................................................................
Alpha-ethyltryptamine ......................................................................................................................................................
Ibogaine ...........................................................................................................................................................................
CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................
CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) ..........................................
VerDate Sep<11>2014
17:31 Jul 13, 2018
Jkt 244001
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
E:\FR\FM\16JYN1.SGM
16JYN1
1233
1235
1237
1238
1246
1248
1249
1258
1475
1480
1503
2565
6250
7008
7011
7012
7019
7023
7024
7031
7035
7048
7081
7104
7118
7122
7144
7173
7200
7201
7203
7222
7225
7249
7260
7297
7298
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 83, Number 136 (Monday, July 16, 2018)]
[Notices]
[Pages 32905-32906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15138]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Siegfried
USA, LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before September 14, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
November 2, 2017, Siegfried USA, LLC, 33 Industrial Park Rd.,
Pennsville, NJ 08070 applied to be registered as a bulk manufacturer
for the basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid............ 2010 I
Dihydromorphine...................... 9145 I
Hydromorphinol....................... 9301 I
[[Page 32906]]
Methylphenidate...................... 1724 II
Amobarbital.......................... 2125 II
Pentobarbital........................ 2270 II
Secobarbital......................... 2315 II
Codeine.............................. 9050 II
Oxycodone............................ 9143 II
Hydromorphone........................ 9150 II
Hydrocodone.......................... 9193 II
Methadone............................ 9250 II
Methadone intermediate............... 9254 II
Morphine............................. 9300 II
Oripavine............................ 9330 II
Thebaine............................. 9333 II
Opium tincture....................... 9630 II
Oxymorphone.......................... 9652 II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers.
Dated: July 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-15138 Filed 7-13-18; 8:45 am]
BILLING CODE 4410-09-P
